Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

ClinicalTrials.gov ID: NCT00063778

Public ClinicalTrials.gov record NCT00063778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Safety and Immunogenicity Trial of an Alphavirus Replicon HIV Subtype C Gag Vaccine (AVX101, Alphavax, Inc.) in Healthy HIV-1 Uninfected Adult Volunteers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to see if different doses of an experimental HIV vaccine are safe and to study how the immune system responds to the vaccine. The vaccine will be tested in healthy, HIV uninfected volunteers. AVX101 contains only one of the many substances that HIV needs to make more copies of itself; therefore, the vaccine cannot cause HIV or AIDS.

Study identification

NCT ID: NCT00063778
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: AlphaVax, Inc.; Industry
Enrollment: 48 participants

Conditions and interventions

Conditions

HIV Infections

Interventions

AVX101 Biological
placebo Other

Biological · Other

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2003
Primary completion: Jun 30, 2005
Completion: Jun 30, 2005
Last update posted: Jul 1, 2012

2003 – 2005

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 5

Facility	City	State	ZIP	Site status
Johns Hopkins University	Baltimore	Maryland	21205-1901	—
Columbia University	New York	New York	10032	—
University of Rochester Medical Center	Rochester	New York	14642-0002	—
New York Blood Ctr- Union Square	The Bronx	New York	10456	—
Vanderbilt University	Nashville	Tennessee	37232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00063778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2012 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00063778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →